Gallagher D Travis, McCullough Chris, Brinson Robert G, Ahn Joomi, Marino John P, Dimasi Nazzareno
Institute for Bioscience and Biotechnology, National Institute of Standards and Technology and the University of Maryland, 9600 Gudelsky Drive, Rockville, MD 20850, USA.
Analytical Sciences, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA.
Pharmaceutics. 2019 Oct 21;11(10):546. doi: 10.3390/pharmaceutics11100546.
Antibody-drug conjugates (ADCs) are a class of biotherapeutic drugs designed as targeted therapies for the treatment of cancer. Among the challenges in generating an effective ADC is the choice of an effective conjugation site on the IgG. One common method to prepare site-specific ADCs is to engineer solvent-accessible cysteine residues into antibodies. Here, we used X-ray diffraction and hydrogen-deuterium exchange mass spectroscopy to analyze the structure and dynamics of such a construct where a cysteine has been inserted after Ser 239 (Fc-239i) in the antibody heavy chain sequence. The crystal structure of this Fc-C239i variant at 0.23 nm resolution shows that the inserted cysteine structurally replaces Ser 239 and that this causes a domino-like backward shift of the local polypeptide, pushing Pro 238 out into the hinge. Proline is unable to substitute conformationally for the wild-type glycine at this position, providing a structural reason for the previously observed abolition of both FcγR binding and antibody-dependent cellular cytotoxicity. Energy estimates for the both the FcγR interface (7 kcal/mol) and for the differential conformation of proline (20 kcal/mol) are consistent with the observed disruption of FcγR binding, providing a quantifiable case where strain at a single residue appears to disrupt a key biological function. Conversely, the structure of Fc-C239i is relatively unchanged at the intersection of the CH2 and CH3 domains; the site known to be involved in binding of the neonatal Fc receptor (FcRn), and an alignment of the Fc-C239i structure with an Fc structure in a ternary Fc:FcRn:HSA (human serum albumin) complex implies that these favorable contacts would be maintained. Hydrogen deuterium exchange mass spectroscopy (HDX-MS) data further suggest a significant increase in conformational mobility for the Fc-C239i protein relative to Fc that is evident even far from the insertion site but still largely confined to the CH2 domain. Together, the findings provide a detailed structural and dynamic basis for previously observed changes in ADC functional binding to FcγR, which may guide further development of ADC designs.
抗体药物偶联物(ADCs)是一类被设计用于癌症治疗的靶向生物治疗药物。生成有效ADC的挑战之一是在IgG上选择有效的偶联位点。制备位点特异性ADC的一种常见方法是将溶剂可及的半胱氨酸残基工程化到抗体中。在这里,我们使用X射线衍射和氢-氘交换质谱来分析这样一种构建体的结构和动力学,其中在抗体重链序列中的Ser 239(Fc-239i)之后插入了一个半胱氨酸。该Fc-C239i变体在0.23 nm分辨率下的晶体结构表明,插入的半胱氨酸在结构上取代了Ser 239,并且这导致局部多肽发生多米诺骨牌式的向后移位,将Pro 238推出到铰链区。脯氨酸在该位置无法在构象上替代野生型甘氨酸,这为先前观察到的FcγR结合和抗体依赖性细胞毒性的消除提供了结构上的原因。FcγR界面的能量估计(7千卡/摩尔)和脯氨酸的差异构象的能量估计(20千卡/摩尔)与观察到的FcγR结合破坏一致,提供了一个可量化的案例,即单个残基处的应变似乎破坏了关键的生物学功能。相反,Fc-C239i在CH2和CH3结构域的交界处结构相对未变;已知该位点参与新生儿Fc受体(FcRn)的结合,并且Fc-C239i结构与三元Fc:FcRn:HSA(人血清白蛋白)复合物中的Fc结构的比对表明这些有利的相互作用将得以维持。氢-氘交换质谱(HDX-MS)数据进一步表明,相对于Fc,Fc-C239i蛋白的构象流动性显著增加,这即使在远离插入位点的情况下也很明显,但仍主要局限于CH2结构域。总之,这些发现为先前观察到的ADC与FcγR功能结合的变化提供了详细的结构和动力学基础,这可能会指导ADC设计的进一步发展。